Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 590

1.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A.

JAMA Oncol. 2019 Sep 29. doi: 10.1001/jamaoncol.2019.4782. [Epub ahead of print]

PMID:
31563959
2.

Geographical and Ethnic Differences Influence Culturable Commensal Yeast Diversity on Healthy Skin.

Leong C, Schmid B, Toi MJ, Wang J, Irudayaswamy AS, Goh JPZ, Bosshard PP, Glatz M, Dawson TL Jr.

Front Microbiol. 2019 Aug 27;10:1891. doi: 10.3389/fmicb.2019.01891. eCollection 2019.

3.

Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study.

Kinoshita T, Nakayama T, Fukuma E, Inokuchi M, Ishiguro H, Ogo E, Kikuchi M, Jinno H, Yamazaki N, Toi M.

Front Oncol. 2019 Aug 6;9:733. doi: 10.3389/fonc.2019.00733. eCollection 2019.

4.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30.

5.

Diagnostic performance of maximum slope: A kinetic parameter obtained from ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast using k-space weighted image contrast (KWIC).

Ohashi A, Kataoka M, Kanao S, Iima M, Murata K, Weiland E, Onishi N, Kawai M, Toi M, Togashi K.

Eur J Radiol. 2019 Sep;118:285-292. doi: 10.1016/j.ejrad.2019.06.012. Epub 2019 Jun 12.

PMID:
31324411
6.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA.

Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392. [Epub ahead of print]

PMID:
31318460
7.

In silico analysis-based identification of the target residue of integrin α6 for metastasis inhibition of basal-like breast cancer.

Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Ishii T, Sato F, Toi M, Itou J.

Genes Cells. 2019 Sep;24(9):596-607. doi: 10.1111/gtc.12714. Epub 2019 Aug 5.

PMID:
31295752
8.

The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation.

Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T.

Radiat Oncol. 2019 Jul 10;14(1):121. doi: 10.1186/s13014-019-1327-8.

9.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x.

10.

New parameters of ultrafast dynamic contrast-enhanced breast MRI using compressed sensing.

Honda M, Kataoka M, Onishi N, Iima M, Ohashi A, Kanao S, Nickel MD, Toi M, Togashi K.

J Magn Reson Imaging. 2019 Jun 18. doi: 10.1002/jmri.26838. [Epub ahead of print]

PMID:
31215107
11.

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M.

Breast Cancer. 2019 Sep;26(5):651. doi: 10.1007/s12282-019-00984-1.

PMID:
31168692
12.

Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels.

Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M.

Int Cancer Conf J. 2018 Jun 1;7(3):107-113. doi: 10.1007/s13691-018-0330-5. eCollection 2018 Jul.

13.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. Erratum in: BMC Cancer. 2019 Jun 24;19(1):620.

14.

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M.

Breast Cancer. 2019 Sep;26(5):637-650. doi: 10.1007/s12282-019-00970-7. Epub 2019 May 24. Erratum in: Breast Cancer. 2019 Jun 5;:.

15.

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.

Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M.

J Glob Oncol. 2019 May;5:1-19. doi: 10.1200/JGO.18.00173.

16.

Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer.

Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K.

Ann Nucl Med. 2019 Aug;33(8):570-578. doi: 10.1007/s12149-019-01364-7. Epub 2019 May 21.

PMID:
31115856
17.

A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey.

Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y.

Surg Today. 2019 Oct;49(10):870-876. doi: 10.1007/s00595-019-01819-4. Epub 2019 May 17.

PMID:
31102022
18.

Insights Into Breast Cancer in the East vs the West: A Review.

Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC.

JAMA Oncol. 2019 May 16. doi: 10.1001/jamaoncol.2019.0620. [Epub ahead of print]

PMID:
31095268
19.

Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes.

Takada M, Toi M.

Int J Clin Oncol. 2019 Jun;24(6):608-613. doi: 10.1007/s10147-019-01448-4. Epub 2019 Apr 13. Review.

PMID:
30982153
20.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

21.

Surgical management of multiple ipsilateral breast cancers.

Benson JR, Jatoi I, Toi M.

Future Oncol. 2019 Apr;15(11):1185-1191. doi: 10.2217/fon-2019-0028. Epub 2019 Mar 29. No abstract available.

PMID:
30924355
22.

Breast cancer over-diagnosis: an adverse consequence of mammography screening - highlights of the 2018 Kyoto Breast Cancer Consensus Conference.

Jatoi I, Benson JR, Toi M.

Future Oncol. 2019 Apr;15(11):1193-1196. doi: 10.2217/fon-2019-0027. Epub 2019 Mar 18. No abstract available.

PMID:
30880457
23.

Real-time 3D Photoacoustic Visualization System with a Wide Field of View for Imaging Human Limbs.

Nagae K, Asao Y, Sudo Y, Murayama N, Tanaka Y, Ohira K, Ishida Y, Otsuka A, Matsumoto Y, Saito S, Furu M, Murata K, Sekiguchi H, Kataoka M, Yoshikawa A, Ishii T, Togashi K, Shiina T, Kabashima K, Toi M, Yagi T.

Version 2. F1000Res. 2018 Nov 19 [revised 2019 Jan 1];7:1813. doi: 10.12688/f1000research.16743.2. eCollection 2018.

24.

Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.

Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S.

Tumour Biol. 2018 Nov;40(10):1010428318811025. doi: 10.1177/1010428318811025.

PMID:
30841783
25.

Alteration of specific cytokine expression patterns in patients with breast cancer.

Kawaguchi K, Sakurai M, Yamamoto Y, Suzuki E, Tsuda M, Kataoka TR, Hirata M, Nishie M, Nojiri T, Kumazoe M, Saito K, Toi M.

Sci Rep. 2019 Feb 27;9(1):2924. doi: 10.1038/s41598-019-39476-9.

26.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M.

Int J Mol Sci. 2019 Feb 24;20(4). pii: E984. doi: 10.3390/ijms20040984.

27.

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.

Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.

28.

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.

Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M.

Breast Cancer (Auckl). 2019 Jan 22;13:1178223418825135. doi: 10.1177/1178223418825135. eCollection 2019.

29.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP.

NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.

30.
31.

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer.

Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M.

Oncotarget. 2018 Dec 14;9(98):37216-37228. doi: 10.18632/oncotarget.26469. eCollection 2018 Dec 14.

32.

Development and clinical translation of photoacoustic mammography.

Shiina T, Toi M, Yagi T.

Biomed Eng Lett. 2018 May 7;8(2):157-165. doi: 10.1007/s13534-018-0070-7. eCollection 2018 May. Review.

33.

Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.

Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M.

Int J Clin Oncol. 2019 Mar;24(3):274-287. doi: 10.1007/s10147-018-1353-9. Epub 2018 Dec 4.

34.

Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging.

Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K.

Magn Reson Med Sci. 2019 Jul 16;18(3):200-207. doi: 10.2463/mrms.mp.2018-0015. Epub 2018 Nov 9.

35.

BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.

Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10642-E10651. doi: 10.1073/pnas.1803177115. Epub 2018 Oct 23.

36.

Digital artery deformation on movement of the proximal interphalangeal joint.

Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M.

J Hand Surg Eur Vol. 2019 Feb;44(2):187-195. doi: 10.1177/1753193418807833. Epub 2018 Oct 18.

PMID:
30335597
37.

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients.

Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M.

Breast Cancer. 2019 May;26(3):282-289. doi: 10.1007/s12282-018-0920-2. Epub 2018 Oct 13.

PMID:
30317464
38.

Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging.

Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M.

Sci Rep. 2018 Oct 8;8(1):14930. doi: 10.1038/s41598-018-33255-8.

39.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M.

Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.

PMID:
30194511
40.

Merkel cell polyomavirus and Langerhans cell neoplasm.

Murakami I, Wada N, Nakashima J, Iguchi M, Toi M, Hashida Y, Higuchi T, Daibata M, Matsushita M, Iwasaki T, Kuwamoto S, Horie Y, Nagata K, Hayashi K, Oka T, Yoshino T, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F.

Cell Commun Signal. 2018 Aug 22;16(1):49. doi: 10.1186/s12964-018-0261-y. Review.

41.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097.

PMID:
30020510
42.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M.

Breast Cancer (Auckl). 2018 Jul 5;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018.

43.

Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer.

Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M.

Photoacoustics. 2018 Jun 20;11:6-13. doi: 10.1016/j.pacs.2018.06.002. eCollection 2018 Sep.

44.

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.

Kiso M, Tanaka S, Saji S, Toi M, Sato F.

Int J Cancer. 2018 Dec 1;143(11):2905-2918. doi: 10.1002/ijc.31645. Epub 2018 Oct 9.

45.

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.

Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M.

Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3.

PMID:
29971625
46.

Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.

Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T.

J Natl Cancer Inst. 2018 Feb 1;110(2):141-148. doi: 10.1093/jnci/djx178.

47.

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1600. [Epub ahead of print]

48.

Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan.

Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M.

PLoS One. 2018 Jun 8;13(6):e0198437. doi: 10.1371/journal.pone.0198437. eCollection 2018.

49.

Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence.

Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M.

Breast Cancer. 2018 Nov;25(6):650-655. doi: 10.1007/s12282-018-0868-2. Epub 2018 May 9.

PMID:
29744670
50.

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M.

Cancer Med. 2018 Jun;7(6):2442-2451. doi: 10.1002/cam4.1516. Epub 2018 May 7.

Supplemental Content

Support Center